← Back to Clinical Trials
Recruiting NCT07367581

NCT07367581 Costotransverse Foramen Block Versus Thoracic Paravertebral Block in Thoracotomy for Lung Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07367581
Status Recruiting
Phase
Sponsor National Cancer Institute, Egypt
Condition Costotransverse Foramen Block
Study Type INTERVENTIONAL
Enrollment 70 participants
Start Date 2026-01-24
Primary Completion 2026-06-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Costotransverse foramen blockThoracic paravertebral plane block

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 70 participants in total. It began in 2026-01-24 with a primary completion date of 2026-06-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to compare the costotransverse foramen block (CTFB) with thoracic paravertebral block (TPVB) in patients undergoing thoracotomy for lung cancer.

Eligibility Criteria

Inclusion Criteria: * Age \> 18 years and ≤ 65 years old. * American Society of Anesthesiologists (ASA) physical status II-III. * Body mass index 18-35 kg/m2. * Patients scheduled for thoracotomies for lung cancer. Exclusion Criteria: * Patient refusal. * History of sensitivity to local anesthetics. * History of psychological disorders. * Contraindication to regional anesthesia, e.g., local sepsis, pre-existing peripheral neuropathies, and coagulopathy. * Severe respiratory, cardiac, hepatic, or renal disease. * Morbid obesity. * Uncooperative patients. * Patients on chronic pain therapy.

Contact & Investigator

Central Contact

Mai M Elrawas, MD

✉ mai.elrawas@nci.cu.edu.eg

📞 00201222177242

Frequently Asked Questions

Who can join the NCT07367581 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Costotransverse Foramen Block. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07367581 currently recruiting?

Yes, NCT07367581 is actively recruiting participants. Contact the research team at mai.elrawas@nci.cu.edu.eg for enrollment information.

Where is the NCT07367581 trial being conducted?

This trial is being conducted at Cairo, Egypt.

Who is sponsoring the NCT07367581 clinical trial?

NCT07367581 is sponsored by National Cancer Institute, Egypt. The trial plans to enroll 70 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology